Specific binding members comprising human antibody antigen binding domains
specific for human transforming growth factor beta (TGF.beta.) bind
specifically isoforms TGF.beta.2 and TGF.beta.1 or both, preferentially
compared with TGF.beta.3. Specific binding members may be isolated and
utilized in the treatment of disease, particularly fibrotic disease and
also immune/inflammatory diseases. Therapeutic utility is demonstrated
using in vitro and in vivo models. Full sequence and binding information
is provided, including epitope sequence information for particularly
advantageous specific binding member which binds the active form of
TGF.beta.2, neutralizing its activity, but does not bind the latent
member.